Uni-Bio Science Group Limited — Capital/Financing Update 2017

Jul 18, 2017

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

==> picture [25 x 24] intentionally omitted <==

==> picture [31 x 37] intentionally omitted <==

==> picture [24 x 29] intentionally omitted <==

==> picture [117 x 51] intentionally omitted <==

UNI-BIO SCIENCE GROUP LIMITED 聯康生物科技集團有限公司* (Incorporated in the Cayman Islands with limited liability) (Stock code: 0690)

VOLUNTARY ANNOUNCEMENT STRATEGIC COOPERATION AGREEMENT

This announcement is made by Uni-Bio Science Group Limited (the “ Company ”, together with its subsidiaries, the “ Group ”) on a voluntary basis.

STRATEGIC COOPERATION AGREEMENT

The board of directors of the Company (the “ Board ”) is pleased to announce that after the trading hours of The Stock Exchange of Hong Kong Limited on 18 July 2017, UniBio Management Limited, a wholly-owned subsidiary of the Company, entered into a strategic cooperation agreement (the “ Agreement ”) with HeungKong Health Medical Limited (“ HeungKong ”), an affiliate of the HeungKong Group. Pursuant to the Agreement, both parties agreed to identify and evaluate in any strategic project opportunities to assess feasibility of co-development in any business area, especially in retail healthcare platform and consumer healthcare information systems in the People’s Republic of China (the “ PRC ”). And with small to medium biomedicine and biotechnology companies as targets, both company jointly engage in international mergers and acquisition activities, on the basis of competitive advantage arises from both parties’ business operations.

INFORMATION ABOUT HEUNGKONG

HeungKong is an affiliate of the HeungKong Group, a PRC based conglomerate with business segments ranging from trade logistics, industrial development, healthcare, financial investments, education, development and construction. The HeungKong Group has been in the healthcare sector for the past 6 years and have established a chain of family health

• For identification purpose only

1

centres which provides a full range of services including medical consultation, Chinese medical therapy, physiotherapy, dental care, drug dispensaries and child clinical psychology. The HeungKong Group also makes use of its self-owned commercial property network in Guangdong to set up locations for trial family health centres, where incorporate advanced eHealth and medical records system to fully embrace the digitalization of healthcare services in PRC.

REASONS FOR AND ADVANTAGES OF ENTERING INTO THE AGREEMENT

The Board considers that, through the strategic cooperation under the Agreement, the parties will be able to form a sustainable strategic partnership beneficial to each other, and integrate the advantages and resources of each other to create greater commercial value by mutually recommending each other in various projects. The Board considers that the entering into the Agreement is in line with the Company’s operation strategy and will expand its footprint in clinic network like that of Heungkong’s family health centres to further expand the distribution of its endocrinology products and having a big data domain for chronic disease (e.g. diabetes and osteoporosis) management, and it is in the interest of the Company and its shareholders as a whole.

The Directors are also pleased to announce that, on 18 July 2017, the Company and a fund related to HeungKong and established by Futec International Holdings Limited, another affiliate of the HeungKong Group (“ HeungKong Great Health Fund ”), entered into a strategic subscription agreement, pursuant to which the Company has agreed to issue and HeungKong Great Health Fund has agreed to subscribe for 873,360,000 new shares at a subscription price of HK$0.138 per new shares.

On behalf of the Board Uni-Bio Science Group Limited Kingsley Leung Chairman

Hong Kong, 18 July 2017

As at the date of this announcement, the Board comprises two executive Directors, namely, Mr. Kingsley Leung (Chairman) and Mr. Chen Dawei (Vice-chairman); and three independent non-executive Directors, namely, Dr. Carl Aslan Jason Morton Firth, Mr. Zhao Zhi Gang and Mr. Chow Kai Ming.

2